CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects.
CYP3A5 genotype has no impact on the trough plasma concentrations of lopinavir and ritonavir in human immunodeficiency virus (HIV)-infected individuals on stable highly active antiretroviral therapy (HAART). This is ascribed to a drug interaction, such that ritonavir by inhibiting CYP3A activity, may occlude the pharmacokinetic consequences of functional polymorphisms in the CYP3A5 gene. In the clinical setting, where lopinavir and ritonavir are always combined, CYP3A5 genotype is of no consequence on the trough plasma concentrations of these drugs.
Estrela
R C E
RC
Divisão de Farmacologia, Coordenação de Pesquisa, Instituto Nacional de Câncer, Rio de Janeiro, Brazil.
Santoro
A B
AB
Barroso
P F
PF
Tuyama
M
M
Suarez-Kurtz
G
G
D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000097:blood*; D023241:Antiretroviral Therapy, Highly Active; D001938:Brazil; D051544:Cytochrome P-450 CYP3A / Q000235:genetics*; D004359:Drug Therapy, Combination; D005838:Genotype; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000097:blood; D006801:Humans; D061466:Lopinavir; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D011744:Pyrimidinones / Q000008:administration & dosage / Q000097:blood*; D019438:Ritonavir / Q000008:administration & dosage / Q000097:blood*
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D061466:Lopinavir; C510164:CYP3A5 protein, human; D051544:Cytochrome P-450 CYP3A; D019438:Ritonavir